37.114.203    REPORTABLE DISEASES AND OTHER CONDITIONS OF PUBLIC HEALTH IMPORTANCE

(1) The following communicable diseases and conditions and other conditions of public health importance are reportable:

(a) AIDS, as defined by the Centers for Disease Control and Prevention, and HIV infection, as determined by a positive result from a test approved by the Federal Food and Drug Administration for the detection of HIV, including antibody, antigen, and all HIV nucleic acid tests;

(b) Anaplasmosis;

(c) Anthrax;

(d) Arboviral diseases, neuroinvasive and nonneuroinvasive (California serogroup, Chikungunya, Eastern equine encephalitis, Powassan, Saint Louis encephalitis, West Nile virus, Western equine encephalitis, Zika virus infection);

(e) Arsenic poisoning (≥ 70 micrograms per liter (µg/L) total arsenic in urine; or ≥ 35 µg/L methylated plus inorganic arsenic in urine);

(f) Babesiosis;

(g) Botulism (including infant, foodborne, other, and wound botulism);

(h) Brucellosis;

(i) Cadmium poisoning (≥ five µg/L total blood cadmium levels; or ≥ three µg/L total cadmium in urine);

(j) Candida auris (C. auris);

(k) Campylobacteriosis;

(l) Chancroid;

(m) Chlamydia trachomatis infection;

(n) Cholera;

(o) Coccidioidomycosis;

(p) Colorado tick fever;

(q) Coronavirus Disease 2019 (COVID-19); 

(r) Cryptosporidiosis;

(s) Cyclosporiasis;

(t) Dengue virus infections;

(u) Diphtheria;

(v) Ehrlichiosis;

(w) Escherichia coli, Shiga toxin-producing (STEC);

(x) Gastroenteritis outbreak;

(y) Giardiasis;

(z) Gonorrheal infection;

(aa) Granuloma inguinale;

(ab) Haemophilus influenzae invasive disease;

(ac) Hansen's disease (leprosy);

(ad) Hantavirus pulmonary syndrome or infection;

(ae) Hemolytic uremic syndrome, post diarrheal;

(af) Hepatitis A, acute;

(ag) Hepatitis B, acute, chronic, perinatal;

(ah) Hepatitis C, acute, chronic;

(ai) Influenza;

(aj) Lead levels in a capillary blood specimen of ≥ 3.5 micrograms per deciliter(µg/dL) in a person less than 16 years of age;

(ak) Lead levels in a venous blood specimen at any level;

(al) Legionellosis;

(am) Leptospirosis;

(an) Listeriosis;

(ao) Lyme disease;

(ap) Lymphogranuloma venereum;

(aq) Malaria;

(ar) Measles (rubeola);

(as) Melioidosis;

(at) Meningococcal disease (Neisseria meningitidis);

(au) Mercury poisoning (≥ ten µg/L total mercury in urine; or ≥ ten  µg elemental mercury/g creatinine in urine; or ≥ ten µg/L elemental, organic, and inorganic blood mercury levels);

(av) Monkeypox;

(aw) Mumps;

(ax) Pertussis;

(ay) Plague;

(az) Poliomyelitis, paralytic or nonparalytic;

(ba) Psittacosis;

(bb) Q-fever (acute and chronic);

(bc) Rabies in a human or animal; exposure to a human by a species susceptible to rabies infection;

(bd) Rubella (including congenital);

(be) Salmonella Paratyphi infection;

(bf) Salmonella Typhi infection; 

(bg) Salmonellosis;

(bh) Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) disease;

(bi) Shigellosis;

(bj) Smallpox;

(bk) Spotted fever rickettsiosis;

(bl) Streptococcus pneumoniae, invasive disease;

(bm) Streptococcal toxic shock syndrome (STSS);

(bn) Syphilis;

(bo) Tetanus;

(bp) Tickborne relapsing fever;

(bq) Toxic shock syndrome (TSS) (nonstreptococcal);

(br) Transmissible spongiform encephalopathies (including Creutzfeldt Jakob Disease);

(bs) Trichinellosis (trichinosis);

(bt) Tuberculosis (TB) including latent tuberculosis infection;

(bu) Tularemia;

(bv) Varicella (chickenpox);

(bw) Vibriosis;

(bx) Viral hemorrhagic fevers; and

(by) Yellow fever.

(2) Also reportable is an outbreak of any communicable disease listed in the "Control of Communicable Diseases Manual" that occurs in an institutional or congregate setting and any unusual incident of unexplained illness or death in a human or animal with potential human health implications.

 

History: 50-1-202, 50-17-103, 50-18-105, 50-18-106, MCA; IMP, 50-1-202, 50-2-118, 50-17-103, 50-18-102, 50-18-106, MCA; NEW, 1980 MAR p. 1579, Eff. 6/13/80; AMD, 1980 MAR p. 2870, Eff. 10/31/80; AMD, 1981 MAR p. 1289, Eff. 10/30/81; AMD, 1986 MAR p. 254, Eff. 2/28/86; AMD, 1987 MAR p. 2147, Eff. 11/28/87; AMD, 1994 MAR p. 1295, Eff. 5/13/94; AMD, 1995 MAR p. 1127, Eff. 6/30/95; AMD, 2000 MAR p. 2986, Eff. 9/22/00; TRANS, from DHES, 2002 MAR p. 913; AMD, 2006 MAR p. 2112, Eff. 9/8/06; AMD, 2013 MAR p. 967, Eff. 6/7/13; AMD, 2017 MAR p. 343, Eff. 3/25/17; AMD, 2019 MAR p. 1745, Eff. 1/1/20; AMD, 2022 MAR p. 1855, Eff. 9/24/22.